Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDX105 for prevention of Regorafenib-induced dermatologic toxicities
NCT05289726Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2022
- Primary completion
- Jul 2022
- Modality
- Hydrogel Systems, Transdermal Patches
- Countries
- 1
01
Overview
A Phase 2 trial of Fufang Danxiong Granules in Hand-foot skin reaction (HFSR), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
Fufang Danxiong Granules
03
Conditions
Hand-foot skin reaction (HFSR)
Beyond the preview
Go deeper on NCT05289726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289726.